中山醫學大學機構典藏 CSMUIR:Item 310902500/25117
English  |  正體中文  |  简体中文  |  全文笔数/总笔数 : 17933/22952 (78%)
造访人次 : 7327806      在线人数 : 210
RC Version 7.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
搜寻范围 查询小技巧：
  • 您可在西文检索词汇前后加上"双引号"，以获取较精准的检索结果
  • 若欲以作者姓名搜寻，建议至进阶搜寻限定作者字段，可获得较完整数据
    •  进阶搜寻


    jsp.display-item.identifier=請使用永久網址來引用或連結此文件: https://ir.csmu.edu.tw:8080/ir/handle/310902500/25117


    题名: Treatment of hepatitis C with direct-acting antiviral agents in renal transplant recipients: a long-term and real-world experience
    作者: Lian, Sheng-Wen Wu ； Chi-Chih Wang ； Ming-Chang Tsai ； Jong-Da
    贡献者: 中山醫學大學
    日期: 2022-06-01
    上传时间: 2022-10-21T03:21:09Z (UTC)
    出版者: 研發處育成中心暨產學合作組
    摘要: Purpose: Direct- acting antivirals (DAAs) are showing encouraging results in hepatitis C virus (HCV) eradication and drug safety, but limited data exist for renal transplant recipients (RTRs). In addition, data are lacking regarding the outcomes of RTRs who failed a previous DAA regimen. Method: We collected data from 17 consecutive HCV-infected RTRs treated with DDAs to evaluate DAA efficacy, relevant side effects, and long-term patient outcomes. Initial DAA regimens included sofosbuvir (SOF)-based regimens in 16 patients (94%) and daclatasvir plus asunaprevir in 1 patient. Results: All patients exhibited a rapid virologic response to therapy and 14 patients (82.3%) achieved a sustained virologic response at 12 weeks after the end of therapy. The anti-HCV regimens were well tolerated, but the tacrolimus level decreased significantly at 2 weeks after treatment. Two RTRs with prior DAA failure were successfully retreated with SOF plus velpatasvir (VEL). Conclusions: IFN-free DAAs were efficacious and well-tolerated in our Asian RTRs. Patients should be carefully monitored to avoid sub-therapeutic immunosuppression in routine practice, regardless of DAA regimens. This is a first report that the combination of SOF and VEL is apparently effective and well-tolerated in RTRs with prior DAAs failure. Further studies are needed to verify our findings.
    URI: https://ir.csmu.edu.tw:8080/handle/310902500/25117
    關聯: 中山醫學雜誌 ； 33卷1期 (2022 / 06 / 01) ， P9 - 16
    显示于类别:[研發處] 期刊論文

    文件中的档案:

    档案 描述 大小格式浏览次数
    Treatment of hepatitis C with direct-acting antiviral agents in renal transplant recipients a long-t.pdf530KbAdobe PDF146检视/开启


    检视Licence

    SFX Query

    在CSMUIR中所有的数据项都受到原著作权保护.

    TAIR相关文章

    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - 回馈